Physician profile
Yevhen Drobot
NPI 1548799851
$4,763.04
in general payments reported to CMS, 2019-2025
35 companies · $870 in 2025
The $870 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $271 · 2021: $713 · 2022: $652 · 2023: $846 · 2024: $744 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,460.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $842.81 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $393.95 | 2020-2025 | |
| Amgen INC. | $289.77 | 2022-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $284.29 | 2021-2025 | Breztri, Farxiga, Seroquel |
| Janssen Scientific Affairs, LLC | $237.50 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.30 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $216.14 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $209.92 | 2021-2024 | |
| Abbvie INC. | $196.33 | 2021-2024 | Linzess, Creon, Vraylar |
| Glaxosmithkline, LLC. | $181.70 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Cequr Corporation | $170.98 | 2023-2024 | Cequr Simplicity |
| Opko Pharmaceuticals, LLC | $157.02 | 2019 | |
| Exact Sciences Corporation | $139.78 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $128.39 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $124.74 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $121.84 | 2019 | |
| Aimmune Therapeutics, INC. | $108.86 | 2024-2025 | Zenpep |
| Dexcom, INC. | $107.99 | 2021-2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $88.04 | 2021-2024 | |
| Corcept Therapeutics | $81.74 | 2025 | Korlym |
| Esperion Therapeutics, INC. | $66.32 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $66.15 | 2022-2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.20 | 2021-2023 | Xifaxan |
| Shield Therapeutics INC | $46.34 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $38.09 | 2023-2024 | Eliquis |
| Phathom Pharmaceuticals, INC. | $37.93 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $24.48 | 2025 | Gemtesa |
| Amarin Pharma, INC. | $18.25 | 2020 | |
| Seqirus USA INC | $17.97 | 2024 | Flucelvax, Fluad |
| Almatica Pharma LLC | $16.22 | 2022 | |
| Ibsa Pharma INC. | $15.28 | 2021 | |
| Astellas Pharma US INC | $15.20 | 2022 | |
| Circassia INC. | $13.85 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.68 | 2022 | |
| Merck Sharp & Dohme LLC | $11.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yevhen Drobot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.